Search research articles
Contact Us
Filters
Showing results (491-500 of 596) with videos related to
Page
of 60
Sort By:
JCO Precision Oncology
|
May 11, 2022
Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
Breast (Edinburgh, Scotland)
|
February 7, 2020
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model
Luisa Carbognin, Michele Simbolo, Anna Caliò, et al.
Cancers
|
July 30, 2020
<i>TP53</i> Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
Francesco Graziano, Nicholas W Fischer, Irene Bagaloni, et al.
Cancers
|
August 23, 2020
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
Giuseppe Lombardi, Valeria Barresi, Stefano Indraccolo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2023
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, et al.
British Journal of Cancer
|
March 14, 2018
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
Chiara Cremolini, Massimo Milione, Federica Marmorino, et al.
Targeted Oncology
|
May 10, 2021
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Pina Ziranu, Eleonora Lai, Marta Schirripa, et al.
ESMO Open
|
April 10, 2019
Benefit from anti-EGFRs in <i>RAS</i> and <i>BRAF</i> wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
Chiara Cremolini, Matteo Benelli, Elisa Fontana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 4, 2025
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial
Federica Miglietta, Manon De Graaf, Claudio Vernieri, et al.
British Journal of Cancer
|
November 17, 2022
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
Maria Vittoria Dieci, Luisa Carbognin, Federica Miglietta, et al.
Page
of 60
Search research articles
Search
Showing results (491-500 of 596) with videos related to
Sort By:
Page
of 60
JCO Precision Oncology
|
May 11, 2022
Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
Breast (Edinburgh, Scotland)
|
February 7, 2020
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model
Luisa Carbognin, Michele Simbolo, Anna Caliò, et al.
Cancers
|
July 30, 2020
<i>TP53</i> Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
Francesco Graziano, Nicholas W Fischer, Irene Bagaloni, et al.
Cancers
|
August 23, 2020
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
Giuseppe Lombardi, Valeria Barresi, Stefano Indraccolo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2023
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, et al.
British Journal of Cancer
|
March 14, 2018
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
Chiara Cremolini, Massimo Milione, Federica Marmorino, et al.
Targeted Oncology
|
May 10, 2021
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Pina Ziranu, Eleonora Lai, Marta Schirripa, et al.
ESMO Open
|
April 10, 2019
Benefit from anti-EGFRs in <i>RAS</i> and <i>BRAF</i> wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
Chiara Cremolini, Matteo Benelli, Elisa Fontana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 4, 2025
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial
Federica Miglietta, Manon De Graaf, Claudio Vernieri, et al.
British Journal of Cancer
|
November 17, 2022
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
Maria Vittoria Dieci, Luisa Carbognin, Federica Miglietta, et al.
Page
of 60